Kalita Ondrej, Kazda Tomas, Reguli Stefan, Jancalek Radim, Fadrus Pavel, Slachta Marek, Pospisil Petr, Krska Lukas, Vrbkova Jana, Hrabalek Lumir, Smrcka Martin, Lipina Radim
Department of Neurosurgery, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, Zdravotníků 248/7, 779 00 Olomouc, Czech Republic.
Department of Health Care Science, Faculty of Humanities, T. Bata University in Zlin, Stefanikova 5670, 760 01 Zlín, Czech Republic.
Cancers (Basel). 2023 Apr 28;15(9):2530. doi: 10.3390/cancers15092530.
Glioblastoma inevitably recurs, but no standard regimen has been established for treating this recurrent disease. Several reports claim that reoperative surgery can improve survival, but the effects of reoperation timing on survival have rarely been investigated. We, therefore, evaluated the relationship between reoperation timing and survival in recurrent GBM. A consecutive cohort of unselected patients (real-world data) from three neuro-oncology cancer centers was analyzed (a total of 109 patients). All patients underwent initial maximal safe resection followed by treatment according to the Stupp protocol. Those meeting the following criteria during progression were indicated for reoperation and were further analyzed in this study: (1) The tumor volume increased by >20-30% or a tumor was rediscovered after radiological disappearance; (2) The patient's clinical status was satisfactory (KS ≥ 70% and PS WHO ≤ gr. 2); (3) The tumor was localized without multifocality; (4) The minimum expected tumor volume reduction was above 80%. A univariate Cox regression analysis of postsurgical survival (PSS) revealed a statistically significant effect of reoperation on PSS from a threshold of 16 months after the first surgery. Cox regression models that stratified the Karnofsky score with age adjustment confirmed a statistically significant improvement in PSS for time-to-progression (TTP) thresholds of 22 and 24 months. The patient groups exhibiting the first recurrence at 22 and 24 months had better survival rates than those exhibiting earlier recurrences. For the 22-month group, the HR was 0.5 with a 95% CI of (0.27, 0.96) and a -value of 0.036. For the 24-month group, the HR was 0.5 with a 95% CI of (0.25, 0.96) and a -value of 0.039. Patients with the longest survival were also the best candidates for repeated surgery. Later recurrence of glioblastoma was associated with higher survival rates after reoperation.
胶质母细胞瘤不可避免地会复发,但针对这种复发性疾病尚未确立标准治疗方案。有几份报告称再次手术可提高生存率,但很少有人研究再次手术时机对生存率的影响。因此,我们评估了复发性胶质母细胞瘤再次手术时机与生存率之间的关系。分析了来自三个神经肿瘤癌症中心的连续未选择患者队列(真实世界数据)(共109例患者)。所有患者均接受了初次最大安全切除,然后根据Stupp方案进行治疗。在病情进展期间符合以下标准的患者被建议进行再次手术,并在本研究中进一步分析:(1)肿瘤体积增加>20-30%或在影像学消失后重新发现肿瘤;(2)患者的临床状态良好(卡氏评分≥70%且世界卫生组织体力状况评分≤2级);(3)肿瘤局限,无多灶性;(4)预期最小肿瘤体积缩小超过80%。对术后生存期(PSS)进行单因素Cox回归分析显示,自首次手术后16个月起,再次手术对PSS有统计学显著影响。经年龄调整对卡诺夫斯基评分进行分层的Cox回归模型证实,对于22个月和24个月的疾病进展时间(TTP)阈值,PSS有统计学显著改善。在22个月和24个月首次复发的患者组比那些较早复发的患者组有更好的生存率。对于22个月组,风险比(HR)为0.5,95%置信区间为(0.27,0.96),P值为0.036。对于24个月组,HR为0.5,95%置信区间为(0.25,0.96),P值为0.039。生存期最长的患者也是再次手术的最佳候选者。胶质母细胞瘤较晚复发与再次手术后较高的生存率相关。